BLA 761125 · Novartis Pharms Corp
Beovu
Brolucizumab-Dbll · Intravitreal
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jul 29, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Oct 7, 2019
Approved uses
2
Original approval plus efficacy supplements
Registered trials
38
24 Phase 3, 1 recruiting
FAERS reports
3,648
2,878 serious, 246 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 26, 2026.
BEOVU ® is indicated for the treatment of: BEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) 1.1 Neovascular (Wet) Age-related Macular Degeneration (AMD) 1.2 Diabetic Macular Edema (DME)
Mechanism: Brolucizumab is a human VEGF inhibitor. Brolucizumab binds to the three major isoforms of VEGF-A (e.g., VEGF 110 , VEGF 121 , and VEGF 165 ), thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, brolucizumab suppresses endothelial cell proliferation, neovascularization, and vascular permeability.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 27, 2022 Supplement 8 · Efficacy LetterLabel
- Oct 7, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
- BEOVU · brolucizumab-dbll 6MG/0.05ML · INJECTABLE, INTRAVITREAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Brolucizumab" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of RTH258 Versus Aflibercept - Study 1Pivotal-lookingCompleted
Alcon ResearchIndustry
NCT02307682 · 1,775 participants · Start Dec 8, 2014 · Primary completion Apr 22, 2017
Drug: Brolucizumab ophthalmic solution; Aflibercept ophthalmic solution · For: Neovascular Age-Related Macular Degeneration; Choroidal Neovascularization
Sites: Fort Worth, Texas
- Efficacy and Safety of RTH258 Versus Aflibercept - Study 2Pivotal-lookingCompleted
Alcon ResearchIndustry
NCT02434328 · 1,048 participants · Start Jul 28, 2015 · Primary completion Apr 5, 2017
Drug: Brolucizumab ophthalmic solution; Aflibercept ophthalmic solution · For: Neovascular Age-Related Macular Degeneration; Choroidal Neovascularization
- Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04005352 · 734 participants · Start Sep 25, 2019 · Primary completion Sep 9, 2022
Drug: Brolucizumab 6 mg; Aflibercept 2 mg · For: Age-related Macular Degeneration
Sites: Phoenix, Arizona; Huntington Beach, California; Loma Linda, California · 118 sites in all
- Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic RetinopathyPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04278417 · 689 participants · Start Nov 19, 2020 · Primary completion Oct 30, 2023
Drug: Brolucizumab 6 mg · For: Proliferative Diabetic Retinopathy
Sites: Tucson, Arizona; Beverly Hills, California; Fullerton, California · 120 sites in all
- Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03481634 · 566 participants · Start Jul 23, 2018 · Primary completion Nov 11, 2020
Drug: Brolucizumab; Aflibercept · For: Diabetic Macular Edema
Sites: Phoenix, Arizona; Beverly Hills, California; La Jolla, California · 116 sites in all
- Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF InjectionsPivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT03710564 · 535 participants · Start Oct 30, 2018 · Primary completion Dec 21, 2020
Drug: Brolucizumab; Aflibercept · For: Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Beverly Hills, California; Huntington Beach, California · 61 sites in all
- Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03917472 · 517 participants · Start Jul 17, 2019 · Primary completion Mar 24, 2021
Drug: Brolucizumab; Aflibercept · For: Diabetic Macular Edema
Sites: Phoenix, Arizona; Tucson, Arizona; Beverly Hills, California · 92 sites in all
- Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein OcclusionPivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT03810313 · 493 participants · Start Jul 3, 2019 · Primary completion Jul 26, 2021
Drug: Brolucizumab 6 mg; Aflibercept 2 mg · For: Central Retinal Vein Occlusion
Sites: Phoenix, Arizona; La Jolla, California; Mountain View, California · 120 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- visual impairment573
- vitreous floaters558
- vision blurred536
- eye inflammation447
- visual acuity reduced435
- retinal vasculitis384
- uveitis364
- vitritis358
- eye pain319
- blindness247
- anterior chamber cell233
- ocular hyperaemia224
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 185 |
| 2020 | 1,252 |
| 2021 | 845 |
| 2022 | 461 |
| 2023 | 341 |
| 2024 | 310 |
| 2025 | 168 |
| 2026 | 84 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Beovu (Brolucizumab-Dbll)
2024 spending
$317K
Beneficiaries
42
143 claims
Per beneficiary
$7,545
$39,859.50 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $596,121 |
| 2021 | $546,835 |
| 2022 | $1,003,821 |
| 2023 | $602,256 |
| 2024 | $316,883 |
Part B: Beovu (Brolucizumab-Dbll) · HCPCS J0179
2024 spending
$13.6M
Beneficiaries
1,552
6,388 claims
Per beneficiary
$8,747
2024 ASP limit $328.68 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $110,737,688 |
| 2021 | $66,538,896 |
| 2022 | $42,274,859 |
| 2023 | $21,308,128 |
| 2024 | $13,575,491 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU, Koh A, Ogura Y, et al. · Ophthalmology 2020 · Clinical Trial, Phase III, Comparative Study
- KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.
Brown DM, Emanuelli A, Bandello F, et al. · Am J Ophthalmol 2022 · Clinical Trial, Phase III, Multicenter Study
- Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Virgili G, Curran K, Lucenteforte E, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Network Meta-Analysis
- Comparative efficacy of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: A systematic review with network meta-analysis.
Butler ETS, Arnold-Vangsted A, Schou MG, et al. · Acta Ophthalmol 2025 · Systematic Review, Comparative Study
- Real-world experience of brolucizumab in nAMD.
Narnaware SH, Bansal A, Bawankule PK, et al. · Indian J Ophthalmol 2024 · Randomized Controlled Trial
- Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis.
Samacá-Samacá D, Hernández-Castillo C, Prieto-Pinto L, et al. · BMJ Open Ophthalmol 2024 · Systematic Review, Network Meta-Analysis
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.